Contact dermatitis. Office diagnosis and management.
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001566:Benzocaine / Q000009:adverse effects; D003877:Dermatitis, Contact / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000473:pathology / Q000628:therapy; D009783:Dermatitis, Occupational / Q000209:etiology; D004781:Environmental Exposure; D005029:Ethylenediamines / Q000009:adverse effects; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D007809:Lanolin / Q000009:adverse effects; D008487:Medical History Taking; D009532:Nickel / Q000009:adverse effects; D010226:Parabens / Q000009:adverse effects; D010655:Phenylenediamines / Q000009:adverse effects; D011188:Potassium / Q000009:adverse effects; D000644:Quaternary Ammonium Compounds / Q000009:adverse effects; D012882:Skin Tests
D000893:Anti-Inflammatory Agents; D005029:Ethylenediamines; D005938:Glucocorticoids; D010226:Parabens; D010655:Phenylenediamines; D000644:Quaternary Ammonium Compounds; D009532:Nickel; D007809:Lanolin; D011188:Potassium; D001566:Benzocaine